Clinical Trial Search

Primary: Percentage of Participants With Drug-related Adverse Events — 33.3; 33.3; 22.2; 88.9 percentage of participants

Primary: Time to Reach Maximum Observed Serum Concentration (Tmax) — 5.2; 6.1 days

Primary: Clinically Relevant Abnormalities for Clinical Laboratory Evaluation, Vital Signs, Lung Function, Carbon Monoxide Diffusing Capacity of the Lung, ECG, Physical…

Primary: Number (%) of Subjects With Drug-related Adverse Events — 28.0; 51.9; 33.3; 92.6 Percentage of participants

Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 6; 5; 5; 6 subjects

Primary: Mean Cmax: Maximum Observed Plasma Concentration for Febuxostat — 2027.1184; 1442.2267; 1730.2468; 1809.3158 ng/mL

Primary: Subjects With at Least One Adverse Event — 4; 4; 11; 15 Participants

Primary: Number of Participants Rated Very Much Improved on the Global Aesthetic Improvement Scale (GAIS) by Prinicple Investigator — 19 participants

Primary: Ketamine-Induced Brain Activity in Regions of Interest During Resting State — 0.4954; 0.2943; 0.4439; 0.3876 percent signal change in brain activity — p=0.259

Primary: Maximum Observed Plasma Concentration (Cmax) of Ticagrelor and Its Active Metabolite AR-C124910XX. — 529; 534; 569; 165 ng/mL

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 13; 4; 3; 2 participants

Primary: Percentage of Participants With an Immune Response to Tetanus and Pneumococcal Vaccinations — 52.6; 51.2; 89.5; 90.2 percentage of participants

Primary: Percentage of Participants With Local (Injection Site) Adverse Events (AEs) After Either Vaccine Dose by Maximum Severity as Assessed by the Clinical Staff — 16.7; 11.8…

Primary: AUC0-tz — 300; 310; 306 ng*h/mL — p=<0.0001

Primary: Number of Subjects With Adverse Effects After a Single Dose of VBP15 — 2; 1; 1; 1 participants